Navigation Links
Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
Date:9/12/2007

September 11, 2007

WASHINGTON, Sept. 12 /PRNewswire-USNewswire/ -- The following is a statement by KCP Chairman Dr. Edward Jones:

Yesterday's FDA Advisory Committee meeting underscores the many considerations that must be factored in to policymaking related to anemia treatment in patients suffering from chronic kidney disease. The kidney community salutes FDA for working with scientists, practicing nephrologists, and other members of the medical community to achieve a consensus on hemoglobin and dosing levels for erythropoietin-stimulating agents (ESAs) based on different patient populations. The community is unified in its belief that patient quality of care and quality of life must be taken into account as physicians treat anemia in kidney patients. Patients with chronic kidney disease and those on dialysis depend on ESAs to stimulate red blood cell production in their bodies.

Anemia-management drugs have been well demonstrated to improve quality of life for kidney patients and provide significant medical benefits. Unlike patients with cancer, patients with chronic kidney disease are permanently affected by anemia, which in turn affects their ability to engage in day-to- day activities that non-patients take for granted -- caring for their families, holding a job, and going to school. Without ESA therapy, ESRD patients may develop hemoglobin levels that are dangerously low. Before ESAs were available, blood transfusions were required in most kidney patients. Transfused patients often suffered from heart failure, iron overload, and other chronic problems.

Several studies have demonstrated improvement in the morbidity and mortality of patients with kidney disease and kidney failure by the appropriate management of their anemia. After extensive review of the results of six new studies, a National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) work group updated its Clinical Practice Guideline on Anemia this month and recommended that ESA therapy in dialysis and non- dialysis CKD patients should target hemoglobin levels in the range of 11 to 12 g/dL. These guidelines are scientifically based.

The FDA panel members reaffirmed current dosing practices and voted against limiting the upper threshold of hemoglobin levels to 11. Additionally, the FDA made it clear that the label instructions were never intended to result in EPO doses being withheld if a patient's hemoglobin level exceeded 12. Further, the committee stressed the need for small incremental dose adjustments of ESAs in an effort to minimize hemoglobin variation around the target. Dr. Ellis Unger specifically raised this as he emphasized the importance of focusing on best practices and the importance of minimizing the rate of rise and rate of fall in hemoglobin. The community urges CMS to consider these findings as they implement the Erythropoietin Monitoring Policy (EMP) used to treat anemia in ESRD patients.

The complexities of ESA dosing were readily apparent during yesterday's Advisory Commission's discussion, and we appreciate the panel's thoughtful consideration of the impact its decision will have on patients.

KCP is a nationwide alliance of representatives from the entire kidney care community, including patients and their advocates, nephrologists, nurses, dialysis care providers, and manufacturers who have joined together to improve the quality of care and quality of life for individuals suffering from kidney disease and kidney failure.


'/>"/>
SOURCE Kidney Care Partners
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
2. Obama Statement on Bush Veto of Stem Cell Bill
3. Statement by Philip Home Chairman of the RECORD Study Steering Committee and Professor of Diabetes Medicine at Newcastle University in England
4. New Position Statement from The North American Menopause Society Addresses Use of Local Estrogen for Treatment of Vaginal Atrophy in Postmenopausal Women
5. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
6. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
7. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
8. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
9. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
10. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
11. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... WILLIAMSTON, Mich. , July 13, 2017  Centurion Medical Products, ... offers its DisImpactor ® fecal impaction removal device for hospice ... ... Patient pain management ... DisImpactor for Hospice can help alleviate patient pain while preventing unneeded ...
(Date:7/12/2017)... July 12, 2017 CarpalAID is a revolutionary new product ... surgery. Carpal tunnel syndrome affects more than 8 million ... the rate of men. The common methods of treating CTS are ... uncomfortable hand braces or gloves. ... CarpalAID is a clear patch worn on ...
(Date:7/11/2017)... , July 11, 2017  Bayer has awarded grants ... countries as part of its prestigious Bayer Hemophilia Awards Program ... of Philadelphia and Uniformed Services University ... are among the winners. Grant recipients were announced last night ... Hemostasis (ISTH) 2017 Congress, Berlin, Germany . ...
Breaking Medicine Technology:
(Date:7/21/2017)... Dalton, GA (PRWEB) , ... July 21, 2017 ... ... provides asset protection and financial consultation services to families and business owners in ... charity drive to raise support for children overcoming sexual assault and physical abuse. ...
(Date:7/21/2017)... Minnesota (PRWEB) , ... July 21, 2017 , ... ... BWBR recently were selected to renovate and improve the Ramsey County Medical Examiners ... adjacent to Regions Hospital, the $2.5 million project is scheduled to start in ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Margarian Law Firm has filed a ... ginger ale for allegedly containing no ginger. Dr. Pepper produces the “Canada Dry” brand ... Gegham Margaryan alleges Canada Dry Ginger Ale claims on its bottle that it is ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... Tears® EyeMist®, the signature product of her research center at Bio-Logic Aqua Research® ... largest population and the greatest number of sufferers of blindness. “We think that ...
(Date:7/20/2017)... ... July 20, 2017 , ... TransPixel Volume 2 is a set of ... FCPX timeline. This effect isolates horizontal and vertical lines of pixels and sorts their ... rotating or flipping animation and can be changed using a drop-down menu. Create amazing ...
Breaking Medicine News(10 mins):